Our PDX models EN
|
Cancers |
N of available PDXs |
Model characterization |
References |
|
|
Breast |
Luminal B |
30 PDXs from primary tumors or bone metastases, some of them resistant to endocrine therapy or CDK4/6 inhibitor |
Clinical data from matched patients, mutations (targeted NGS panels), copy number (WES or CGH), IHC, RT-PCR |
Montaudon 2020, Cottu 2014, Cottu 2012, Coussy 2019, Marangoni 2007 Marangoni 2018, Coussy 2019 |
|
Her2 |
10 PDX, some of them resistant to various HER2 targeted therapies |
Clinical data from matched patients, mutations (targeted NGS panels), gene expression, IHC, drug response to anti HER2 and chemotherapies |
Marangoni 2007, Marangoni 2018, Coussy 2019 |
|
|
Triple Negative |
More than 80 PDXs, including all different TNBC molecular subtypes |
Clinical data from matched patients, mutations (targeted NGS panels), RNAseq, CGH arrays, BRACaness signature, drug response to different chemotherapies |
Marangoni 2007, Marangoni 2009, Reyal 2012, Legrier 2016, Romanelli 2012, Hatem 2016, Marangoni 2018 Coussy 2019, Coussy 2020a, Coussy 2020b, Coussy 2020c |
|
|
Chordoma |
/ |
13 PDXs from neurosurgery tumor samples |
Clinical data from matched patients, mutations (targeted NGS panels), copy number (CGH), IHC, RT-PCR, drug response to different targeted therapies (alone and in combination) |
In preparation |
|
Lung |
NSCLC |
About 35 PDXs, including neuroendocrine and sarcomatoid carcinoma, and one PLK1 inhibitor-resistant variant |
Clinical data from matched patients, mutations (targeted NGS panels), copy number (CGH), IHC, RT-PCR, drug response to different chemotherapies or targeted therapies (alone and in combination) |
Montaudon 2021, Raimbourg 2017, Bieche 2014, Arrouss 2013, Némati 2009 |
|
SCLC |
About 5 PDXs |
Drug response to different chemotherapies (alone and in combination) |
Némati 2010, Rezaï 2007, Decaudin 2005, Decaudin 2002 |
|
|
Ovarian |
/ |
About 30 PDXs |
Mutations (targeted NGS panels), BRACaness signature, drug response to different chemotherapies |
Bougherara 2017 |
|
Prostate |
/ |
One model (PAC120) and its castration-resistant variant |
Mutations (targeted NGS panels), drug response to different chemotherapies, endocrine therapies and targeted therapies |
Barbosa-Desongles 2013, Kukuk 2011, Dahmani 2010, Legrier 2007, Legrier 2003, Oudard 2003, Decaudin 2001, de Pinieux 2001 |
|
Uveal melanoma |
/ |
About 40 PDXs, some of them from patient’s metastases |
Clinical data from matched patients, mutations, copy number (CGH), IHC, drug response to different chemotherapies or targeted therapies (alone and in combination) |
Decaudin 2020, de Koning 2019, Decaudin 2018, Crépin 2017, Amirouchene-Angelozzi 2016, Carita 2016, van Essen 2016, Piperno-Neumann 2016, Carita 2015, Amirouchene-Angelozzi 2014, Némati 2014, Laurent 2013, Madic 2012, Némati 2010 |